Case Report Open Access

Rapid Development of Type 1 Diabetes Mellitus after Initiation of Anti-PD-1 Therapy

Muneeb Shah, Luke Maxfield, Rehan Feroz and Kevin Donohue
Int J Cancer Clin Res Volume 3, Issue 4

Abstract: Programmed death protein 1 (PD-1) is a receptor on immune cells that serves as a checkpoint and plays an important role in preventing the activation of T-lymphocytes. Malignant cells are known to activate this receptor, thereby allowing them to evade immune surveillance. Programmed death 1 immune-checkpoint inhibitor antibodies (anti-PD-1), such as nivolumab, act to revamp the immune response against tumor cells by preventing activation of this PD-1 receptor.

PDF   | Full Text   DOI: 10.23937/2378-3419/3/4/1066

Review Article Open Access

Culture of Circulating Tumor Cells - Holy Grail and Big Challenge

Tianyu Guo, Claire S Wang, Wen Wang and Yongjie Lu
Int J Cancer Clin Res Volume 3, Issue 4

Abstract: Circulating tumor cells (CTCs), the most important representation of 'liquid biopsy', provides a minimally invasive approach to tumor tissue, and has been a hot topic in cancer research for years. CTCs bear great potential to provide a surrogate for traditional biopsy, and the culture of CTCs is essential to investigate the biological features of CTCs and their roles in cancer metastasis as well as to provide the opportunity for in vitro therapeutic sensitivity tests to guild treatment selection.

PDF   | Full Text   DOI: 10.23937/2378-3419/3/4/1065

Original Article Open Access

Dosimetric Study on the Consequences of Replacing the mMLC Collimator Used for Intracranial SRS by an Integrated MLC-160

Tania Santos, Tiago Ventura, Miguel Capela and Maria do Carmo Lopes
Int J Cancer Clin Res Volume 3, Issue 4

Abstract: At IPOCFG, stereotactic radiosurgery is performed using an add-on micro-multileaf collimator (3 mm minimum leaf width), m3, with full advanced integration in a linear accelerator equipped with a standard 82 leaf multileaf collimator with 1 cm leaf width. This work aimed to evaluate if it would be possible to dispense the use of the m3 if the standard MLC was replaced by a MLC-160 with 5 mm leaf width at isocenter.

PDF   | Full Text   DOI: 10.23937/2378-3419/3/4/1064

Original Article Open Access

Estimating Relapse Free Survival as a Net Probability: Regression Models and Graphical Representation. An Application of a Large Breast Cancer Case Series

Annalisa Orenti, Elia Biganzoli and Patrizia Boracchi
Int J Cancer Clin Res Volume 3, Issue 4

Abstract: In most clinical studies, the evaluation of the effect of a therapy and the impact of prognostic factors is based on relapse-free survival. Relapse free is a net survival, since it is interpreted as the relapse-free probability that would be observed if all patients experienced relapse sooner or later. Death without evidence of relapse prevents the subsequent observation of relapse, acting in a semi-competing risks framework. Relapse free survival is often estimated by standard regression models after censoring times to death.

PDF   | Full Text   DOI: 10.23937/2378-3419/3/4/1063

Pilot Study Open Access

Cancer Risk among Physicians is Different from that among Non-Physicians: An Observational Pilot Study

Hyun Young Kim
Int J Cancer Clin Res Volume 3, Issue 4

Abstract: We conducted a retrospective, case-control study on cancer risk among physicians and non-physicians at a health screening center. A total of 1,110 Korean subjects aged 30 to 65 years were assessed for cancer risk. A physician group (primary clinic, N = 147, tertiary hospital, N = 123) and non-physician group (N = 840) were included.

PDF   | Full Text   DOI: 10.23937/2378-3419/3/4/1062

Original Article Open Access

Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer

Takeshi Kotake, Yuichiro Kikawa, Sachiko Takahara, Shigeru Tsuyuki, Hiroshi Yoshibayashi, Eiji Suzuki, Yoshio Moriguchi, Hiroyasu Yamashiro, Kazuhiko Yamagami, Hirofumi Suwa, Toshitaka Okuno, Takahito Okamura, Takashi Hashimoto, Hironori Kato, Akihito Tsuji and Masakazu Toi
Int J Cancer Clin Res Volume 3, Issue 4

Abstract: Introduction: A multicenter observational retrospective study was conducted to assess the clinical response and survival impact, especially post-progression survival impact, of eribulin monotherapy in HER2-negative advanced or metastatic breast cancer (A/MBC) patients. Patients and methods: This retrospective observation cohort study contains 110 A/MBC patients treated with eribulin monotherapy during April 2011 and August 2014 in 12 Kyoto Breast Cancer Research Network (KBCRN) institutions.

PDF   | Full Text   DOI: 10.23937/2378-3419/3/4/1061

Volume 3
Issue 4